Essex Bio-Tech Buys Back 191,000 Shares; Treasury Holdings Rise to 1.55 Million

Bulletin Express08-06

Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per share. The volume-weighted average purchase price was approximately HKD 2.3705, bringing total cash outlay to HKD 0.45 million.

Post-transaction, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased by 0.03% to 565.46 million. Treasury stock rose from 1.36 million to 1.55 million shares, while the company’s total issued share capital remained unchanged at 567.01 million shares.

The repurchase forms part of the mandate granted by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative purchases under this mandate now stand at 1.55 million shares, equivalent to 0.27% of the company’s issued share capital at the mandate date.

In line with Hong Kong Listing Rule 10.06(3)(a), Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 5 September 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163442080?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163442080","market":"hk","top_or_hot":-1,"title":"Essex Bio-Tech Buys Back 191,000 Shares; Treasury Holdings Rise to 1.55 Million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per share. The volume-weighted average purchase price was approximately HKD 2.3705, bringing total cash outlay to HKD 0.45 million.</p>\n<p>Post-transaction, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased by 0.03% to 565.46 million. Treasury stock rose from 1.36 million to 1.55 million shares, while the company’s total issued share capital remained unchanged at 567.01 million shares.</p>\n<p>The repurchase forms part of the mandate granted by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative purchases under this mandate now stand at 1.55 million shares, equivalent to 0.27% of the company’s issued share capital at the mandate date.</p>\n<p>In line with Hong Kong Listing Rule 10.06(3)(a), Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 5 September 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech Buys Back 191,000 Shares; Treasury Holdings Rise to 1.55 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech Buys Back 191,000 Shares; Treasury Holdings Rise to 1.55 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-06 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per share. The volume-weighted average purchase price was approximately HKD 2.3705, bringing total cash outlay to HKD 0.45 million.</p>\n<p>Post-transaction, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased by 0.03% to 565.46 million. Treasury stock rose from 1.36 million to 1.55 million shares, while the company’s total issued share capital remained unchanged at 567.01 million shares.</p>\n<p>The repurchase forms part of the mandate granted by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative purchases under this mandate now stand at 1.55 million shares, equivalent to 0.27% of the company’s issued share capital at the mandate date.</p>\n<p>In line with Hong Kong Listing Rule 10.06(3)(a), Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 5 September 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1163442080","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163442080","pubTimestamp":1786008384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"埃塞克斯生物技术公司回购 191,000 股股票；国债持有量增至155万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per share. The volume-weighted average purchase price was approximately HKD 2.3705, bringing total cash outlay to HKD 0.45 million.\nPost-transaction, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased by 0.03% to 565.46 million. Treasury stock rose from 1.36 million to 1.55 million shares, while the company’s total issued share capital remained unchanged at 567.01 million shares.\nThe repurchase forms part of the mandate granted by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative purchases under this mandate now stand at 1.55 million shares, equivalent to 0.27% of the company’s issued share capital at the mandate date.\nIn line with Hong Kong Listing Rule 10.06(3)(a), Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 5 September 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163442080","isCrawlerRequest":true}